The Oslo Cancer Cluster Management Team has significant industry experience and builds on a strong national and international network.
Ketil F. Widerberg, MBA, is General Manager of Oslo Cancer Cluster. He builds on a long experience in realizing new projects within oncology in the biopharmaceutical company Photocure ASA in collaboration with academic institutions and international commercial partners.
Ketil has a broad operational experience ranging from explorative project management to being responsible for business development.
Widerberg’s educational background spans from preclinical medical school to management studies. He also holds a MBA from the University of Cambridge.
Jutta Heix, International advisor at Oslo Cancer Cluster, is a life science professional with more than 15 years of industry experience.
Jutta holds a PhD from the University of Heidelberg / German Cancer Research Center, and worked in different Business Development positions in international pharma and biotech companies.
Jutta is responsible for the cluster’s international cluster-cluster network and partnering activities. She organizes the annual Cancer Crosslinks meeting in collaboration with industry partners and is the contact point for the Immuno-Oncology Consortium.
D.B.R.K Gupta Udatha
Gupta Udatha is Project Manager for the Horizon 2020 EU project “Personalized Medicine Innovation through Digital Enterprise Solutions: PERMIDES”. Gupta Udatha received his PhD from Chalmers University of Technology - Sweden. He has led the development of multi-national collaborations and coordinated research groups in academia & industry.
Dr. Udatha has 10 years’ of R&D experience in the fields of bioinformatics, systems biology and big data analytics of biopharmaceutical data. He is also an entrepreneur and supporter of open-access publishing.
Espen Haakstad is Wenche Gerhardsen’s temporary replacement and will be seeing to the cluster’s and incubator’s internal and external communications in her absence.
He has previously worked as a Science Journalist at the University of Oslo and as a Communication Advisor at The Norwegian Research Council. Espen holds a Master’s degree in Rhetoric and has worked 16 years with news and communications.
Wenche Gerhardsen is currently on parental leave until August 2018. Please contact Espen Haakstad for any communications related issues.
Wenche is responsible for internal and external communications in the cluster and incubator, including e.g. our webpages, social media, media-relations and marketing.
She has previously worked at The Norwegian Defence Research Establishment (FFI) as Senior Advisor and Communications Advisor and she has a background as a news- and science journalist. Her master’s degree is in political science. You can read more about Wenche’s background at LinkedIn.
Charlotte Wu Homme
Charlotte Wu Homme is responsible for membership and events coordination for Oslo Cancer Cluster. This includes R&D network meetings and other initiatives for cluster members.
She has served different international organizations based in the US, Norway, and throughout Asia. Charlotte Homme attained her Master of Science in Project Management from The George Washington University.
Bente Prestegård is senior advisor in Oslo Cancer Cluster, where she mainly works on the educational agreement with Ullern Upper Secondary School and oncology clinical studies. She is also the main accountant.
Bente has a background from business administration, as a pharmaceutical sales representative and she has worked with collaboration agreements between Oslo University Hospital and the pharmaceutical industry.
Eva S. Dugstad
Eva S. Dugstad started in the position as Director for Business Development in the Norwegian Radium Hospital Research Foundation (RF) in 2017, and is also serving as a special advisor for Oslo Cancer Cluster.
She holds a Cand. Pharm. degree from the University of Oslo. Her previous appointments include the President and Exec.Vice President at the Institute for Energy Technology (IFE) and Research Director for Sector Nuclear Technology and Physics also at IFE, where radiopharmaceuticals was a priority.